Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China

• Main Authors: Aodi Huang (Author), Xia Xu (Author), Lin Tang (Author), Lifang Huang (Author), Jun Li (Author), Xue Zhang (Author), Jiajie Liu (Author), Yang Zhou (Author), Bingling Zhang (Author), Lei Wang (Author), Qian Zhang (Author), Zemei Zhou (Author), Yu Wang (Author), Xiaoqi Wang (Author), Qianqian Liu (Author), Siyu Liu (Author), Zundong Yin (Author), Fuzhen Wang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTDTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence...